A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.
|Translated title of the contribution||Evaluation of platelet aggregation, some blood clotting parameters, and the lipid profile in patients treated with Suloctidyl|
|Number of pages||10|
|Journal||Gazzetta Medica Italiana|
|Publication status||Published - 1982|
ASJC Scopus subject areas